Good point. If you go by the past, yes, historically controlled trials seems to let in questions that clouds the results. In reality I would disagree but I am not the FDA. FDA has up to now been fairly pacific, they want a well controlled study in adults for that indication. Off lable use would provent this from happening. Adults still would get funding from the insurer, we have plenty of evidence of effectiveness from the 70 odd patients already treated.
Waiting a few months seems good to me.
MSB would be fairly well financed with around 100 children and 200 adults with GVHD that have no other alternatives. No rush for results in the P3 for adults. We could look at treatment failures over say 2 years as a primary. We could also look at cGVHD development. This would put us in a position to be the preferred 2 line treatment for aGVHD.
- Forums
- ASX - By Stock
- MSB
- 2024 Here we go again.
2024 Here we go again., page-463
-
- There are more pages in this discussion • 481 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B |
Open | High | Low | Value | Volume |
98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 71720 | 94.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.5¢ | 10463 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 65720 | 0.940 |
3 | 31070 | 0.935 |
4 | 85753 | 0.930 |
2 | 9000 | 0.925 |
5 | 75776 | 0.920 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 10463 | 1 |
0.950 | 50000 | 2 |
0.955 | 64000 | 1 |
0.960 | 30220 | 3 |
0.965 | 44050 | 3 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |